India: Patents Ordinance 2004: "Generically" Speaking

Last Updated: 27 January 2005

By Mustafa Safiyuddin and Ajay Shaw, DSK Legal

Should generic drug manufacturers, who have a substantial market share of the Indian drug industry, have any immediate worries arising from the new patent regime for pharmaceutical products, introduced by the Patents (Amendment) Ordinance 2004, effective from January 1, 2005?

The answer appears to be in the negative - the generic drug manufacturers are here to stay. There are three reasons for this: Firstly, majority of the drugs manufactured in India are off patents or are not patentable in India for lack of novelty. Secondly, several ‘mail box’ applications have been filed prior to January 1, 2005 for the grant of pharmaceutical product patents. Examination or processing thereof is to commence only now, i.e., from the beginning of 2005. However, the Indian Patent Office lacks sufficient resources to process them expeditiously. The problem of a huge backlog of pending mailbox applications is likely to multiply with the expected increase in patent filings under the new regime. Thirdly, there are sufficient provisions in the amended patent law which will facilitate generic drug manufacturers to continue to thrive, at least for some years to come.

In this article, the authors intend to analyse some of the provisions of the amended patent law that may be beneficial to generic drug manufacturers. These may be conveniently divided under the following heads: (1) ‘Mail box’ applications, i.e. pharmaceutical product patent applications filed under the ‘mail box’ system prior to January 1, 2005. (2) New applications, i.e., pharmaceutical patent applications that may be filed post January 1, 2005 under the new patent regime.

Mail box applications

The generic drug manufacturers would want to know whether they can, without fear of any potential liability, continue to manufacture the generic versions of drugs for which patent applications have been made prior to January 1, 2005 under the ‘mail box system’, the processing of which will commence only now. In this context, a new section 11A(7) introduced by the Ordinance is relevant. In substance, it provides that patent infringement proceedings can only be instituted after a patent has been granted (i.e. post grant). It further provides that in respect of ‘mail box’ applications, patent rights shall accrue to a patentee only from the date of the grant of the patents i.e. there can be no liability by way of damages for any ‘infringement’ prior to the date of the grant of the patent.

The effect of this provision is that a generic drug manufacturer will not incur any liability in respect of a product covered by a ‘mail box’ application until the date of the actual grant of the patent in respect thereof. Thus, so long as a patent for a ‘mail box application’ is not actually granted / sealed, the generic drug manufacturer can freely manufacture the same without any fear of liability for damages.

One other implication of the above provision is that the effective patent term of products covered by the ‘mail box’ application will be much less than 20 years. This is because the patent term of 20 years is to commence from the date of the application, whereas the patent rights come into existence only after the grant of the patent, which is likely to be some years after the application date.

One subtle issue may also be noted. Before the Ordinance came into force and whilst ‘mail box’ applications were being accepted, Section 3 of the Patent Act provided that ‘new use for a known substance’ was not patentable subject matter. Hence new pharmaceutical uses for a known substance was excluded from patentability. However, the Ordinance amends Section 3 so as to provide that ‘mere new use for a known substance’ would not be patentable. The word ‘mere’ restricts the scope of non-patentable subject matter and widens the scope of patentability. Accordingly, ‘new pharmaceutical use for a known substance’, even though the substance itself is known and comprises part of the ‘state of the art’, would still be patentable. Thus the ‘new discovery’ that the consumption of the known substance, aspirin, can also be useful in thinning the blood can be patentable by making a claim for ‘use of aspirin in making a medicament for use in the prevention of blood clots.’

It is the opinion of the authors that for ‘mail box’ applications, patents should not be granted for new pharmaceutical uses for a known substance if the substance itself comprised part of the ‘state of the art’ as of the date of the application. This is because on the date of such ‘mail box’ application (which is material for considering novelty and the patent term, if granted) the same did not constitute patentable subject matter by virtue of the old Section 3 referred to above.

New applications

The scheme of the patent regime suggests that novelty and ‘state of the art’ is to be determined as of the date of the patent application. Similarly, the patent term of 20 years commences from the date of the application. In respect of the ‘mail box’ applications, rights and privileges conferred upon a patentee commences from the date of the grant of the patent. However, in respect of pharmaceutical product patent applications made after January 1, 2005, such rights and privileges accrue to a patentee upon publication of the patent application by the patent authorities in the patent journal during the examination process, though infringement proceedings in respect thereof can only be instituted after the patent has been granted (New Section 11(A)7).

Thus in respect of such new applications made after January 1, 2005, a generic drug manufacturer can be prevented from manufacturing the product covered by the application only after the grant of such patent. No damages for infringement can be claimed in respect of such manufacture until the date of publication of the application by the patent authorities. Since the rights and privileges accrue to the patentee from the date of publication, one view is that damages for patent infringement may be claimed from the date of publication and not only from the date of grant of the patent. However, in this context section 111 of the Patent Act of 1970 is also relevant. It provides that no damages for patent infringement can be claimed against an alleged infringer ‘who proves that at the date of the infringement he was not aware and had no reasonable grounds for believing that the patent existed.’ In view of the authors this defense may be available so long as a patent has not been granted because until then the question of ‘patent existed’ cannot arise. Hence it is not certain whether damages can be claimed from the date of publication of the application since during such period the patent would not have existed. From the date of the grant of the patent, an infringer would be liable for damages unless he is able to prove that he had no knowledge or had no reason to believe that a patent existed.


The expediency of an Ordinance has been resorted to in an endeavour to comply with India’s obligations under Agreement on Trade Related Aspects of Intellectual Property Rights (popularly known as "TRIPS") by the January 1, 2005 deadline. However, the Ordinance, seeking to amend the Patents Act, 1970 could lapse if it is not approved by Parliament during the monsoon session. It is questionable as to whether the Government should resort to a Presidential Ordinance bringing about far reaching changes in the patent law without a Parliamentary debate in the first place, in respect of issues on which views have been divided across the country.

However even if the Ordinance is approved / passed by the Parliament, the generic drug industry is likely to continue to flourish by having recourse to the beneficial provisions of the patent regime and due to the known delays in processing the patent applications by the patent authorities.

© DSK Legal, 2005

The views expressed in this article are those of the authors and do not represent the views of the firm. This article does not purport to be professional advice, nor a complete or comprehensive study on the subject. It is recommended that professional advice be sought before taking any action pursuant to any matter contained in this article.

Originally published in the Business Line on January 11, 2004

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.